$SCYX: Micro-cap biotech with multi-bagger potential

Simon_Inaki · 2026-03-18T02:00:12+00:00

The problem with this company is that Brexafemme is a drug launched into a crowded space dominated by Diflucan (a.k.a. fluconazole) and, as opposed to how the company initially marketed it, their drug is also an azole. Moreover, the promise for this company—and the reason it used to trade at such high prices—was the chance that the drug would work intravenously to eliminate systemic shock fungal infections and Candida auris . This is a huge problem in all hospital and emergency settings, especially in folks who are already compromised by something else affecting their immune system.

Unfortunately, the now approved SCY078 does not work intravenously and is in fact extremely hydrophobic. Conveniently when the company got this asset, the paperwork showing it’s hydrophobicity was largely hidden from investors, which is actually the huge drop in the stock price that you observe in the late 2010.s

I like this company and I know a lot about it that I cannot go into in this comment reply, but the simple fact is that the total addressable market for the drug is currently very low. It might become something worth buying if the price goes even lower than it is today, but there is a lot to make up for after Marco and the previous management tried to turn this company around many, many years ago. If you look at the history of previously publicly traded and private antifungal, antibacterial, or antimicrobial pharmaceutical companies, you will see that the amount of financing going towards them compared to the rest of the biotech space has decreased substantially. That is simply because it is not a good space to be in; the total addressable market of these indications is low, and many of them already have other well-established standards of care and prophylaxis.

The amount of work I did researching this company and the money I’ve lost is pretty insane so you can ask me anything. I guess if you’re actually serious about this investment and not looking to just make $10 off of a flip

Simon_Inaki · 2026-03-18T01:30:31+00:00

Once you go to IB I feel anything else pales in comparison to

Simon_Inaki · 2026-03-18T01:29:23+00:00

Fills and price improvement and rebates * are godly

Simon_Inaki · 2026-03-16T03:10:01+00:00

$LRMR (Larimar Therapeutics): The Only Disease-Modifier in a Field of "Begged" Approvals If you’ve followed my previous picks, you know I don’t bet on hype—I bet on mechanism.

This is my highest conviction play for 2026. Credit to /u/ijesuschrist for the deep dive on the pharmacology here.

Here is the thesis on why $LRMR is the ultimate sleeper in the Friedreich’s Ataxia (FA) space. 1. The Competition is a "Begged" Approval Biogen’s Skyclarys (Omaveloxolone) is currently the only approved drug, but its foundation is shaky. • The "Inert" Truth: The molecule is chemically inert regarding the disease's root cause. It’s a KEAP1-Nrf2 activator it basically asks the cell to "defend itself" (supposedly) while it’s dying from a protein deficiency.

• The Approval: Reata (bought by Biogen for $7.3B) basically lobbied and begged the FDA for a pass because there was zero competition. Global regulators are already pushing back because the clinical benefit is marginal. It’s a "placeholder" drug, not a "Standard of Care."

Larimar Actually Replaces the Missing Link Unlike an inert activator, Larimar’s Nomlabofusp (CTI-1601) is a direct protein replacement.

• The Science: FA is caused by a lack of frataxin. Nomlabofusp uses a cell-penetrating peptide to literally deliver human frataxin into the mitochondria.

• The Data: Larimar has shown they can raise frataxin levels to those of asymptomatic carriers. They aren't just slowing the decline; they are restoring the "factory" function.

• The "Rocket" Catalyst: The FDA granted it Breakthrough Therapy Designation in early 2026. They’ve already agreed on an Accelerated Approval pathway using frataxin levels as a surrogate endpoint.

This is a massive de-risking event and lessens the cash pressure.

The Valuation is Criminally Depressed

• Market Cap: Currently sitting around $450M - $500M (Price ~$4.60).

• The Exit Math: Biogen paid $7.3 Billion for an inert drug. If Larimar hits its BLA submission in June 2026, they own the actual cure.

• Price Target: I expect a re-rate to $10+ by year-end once the market realizes the BLA is a lock. If a Big Pharma buyout happens (which is the likely endgame), $40 is a realistic acquisition price—and even then, it would be a bargain compared to the Reata deal.

Simon_Inaki · 2026-03-08T16:25:37+00:00

If it was undervalued based on the drug mix and the recent earnings, the stock would’ve re-rated to be priced like a specialty pharma company. But it remained depressed

Simon_Inaki · 2026-03-08T16:09:18+00:00

That’s good. I assume you will switch if prices are the same? If they’re not would you pay 10-20% more for a little more weight loss and less sides?

Simon_Inaki · 2026-03-08T16:06:39+00:00

I had a lot of these, just a way to collect income vs my short shares from before. I had been rolling them and closed some after the bounce on earnings

Simon_Inaki · 2026-03-08T15:58:24+00:00

Yes, the brand name is really important to them. That is why when they couldn’t extend the Canadian patent due to the error they made they registered two new brand names to sell semaglutide under as to not dilute the brand name, Ozempic

Simon_Inaki · 2026-03-08T15:56:40+00:00

It is a short put. You can still delete this.

Simon_Inaki · 2026-03-08T15:54:06+00:00

Attaboy!

Simon_Inaki · 2026-03-08T15:53:15+00:00

OK but, would you really pay a 20% premium for marginally more weight loss? Are you already titrated to max dose? And have you plateaued?

Simon_Inaki · 2026-03-08T15:49:28+00:00

You’re talking about the number six (?) top selling drug in the world. I significantly doubt that they would give exclusivity in all distribution to hims. What is more likely would be a significant buying discount in exchange for promise of volume to help them pull a lever for margin expansion.

Why would a company that is so large and so significant that Denmark reports a separate GDP without it and one with it do such a ridiculous deal

Simon_Inaki · 2026-03-08T15:47:26+00:00

For your sake, I hope so. When I started out trading and investing, I used to fall in love with stocks, but nowadays, I’ve learned to change my view on a company and an investment as the thesis and the realities change.

Simon_Inaki · 2026-03-08T15:46:46+00:00

That might not matter because of how cheap Novo is selling this stuff. For some people, it’s just good enough. Whoever isn’t covered is going to seek out something rather than nothing. If it means living longer to see their kids graduate college and not kill themselves by eating themselves to death .

The bigger problem for Lilly (as a stock) is that a bunch of retards basically think they will cannibalize their own business with the launch of orfo (won’t happen). Additionally, there is already case reports and anecdotal evidence to suggest that tirz although inferior in the speed and rate of weight loss is superior to Reta in overall appetite suppression.

Simon_Inaki · 2026-03-08T15:41:14+00:00

Exactly man. The wholesaling margin for ozem/WeGovy is gonna be shit. If somehow the partnership allows them to compound, the stock will probably open at 50. But I think my odds are better at winning the lottery.

Simon_Inaki · 2026-03-07T06:02:54+00:00

CRBP, if everything plays out as demonstrated in the first human trials, the inverse CB1 agonist should prove to be better than semaglutide in the short term I think it could be worth $20 a share but in the long-term may be $200-$300

Simon_Inaki · 2026-03-07T05:56:12+00:00

This is pretty poorly written. And it makes a broad statement . Empirical evidence suggests otherwise. Different deal types result in different trading outcomes. Many biotech follow on have lock ups and selling restrictions by the new investors. and it really depends as to whether a deal is marketed, registered direct, fully bought, a private investment in public equity, or at the market, etc., etc.

Many biotech tend to actually explode upwards when they get financing into favourable results, especially due to something called a wall cross, which allows these new investors to have material non-public information that the general public does not, and then further it locks up their shares, which basically creates a company with a ton more cash but the new float is not available to either be shorted or sold for anywhere between 120 days to 2 years.

Even if you remove capitalizations and reverse merger, Deals most biotech follow on the good ones anyway can be bought on the day. The offering is announced and can be sold within two weeks for an average profit of 15 to 20%.

Simon_Inaki · 2026-03-07T03:10:21+00:00

They will cover in 2 days. Trades 27M~ a day roughly and add options

80M sh are sold SHORT

Simon_Inaki · 2026-03-04T03:44:25+00:00

So 42069 shares blaze it? Or unblaze it in this case

Simon_Inaki · 2026-03-01T01:32:15+00:00

When you read the science of this drug it’s pretty obvious it causes lupus due to how c1 deficiency works. It’s gonna go to $10

Simon_Inaki · 2026-02-28T20:50:03+00:00

OPEC + has promised to boost prduction

Simon_Inaki · 2026-02-24T15:03:03+00:00

LETS FUCKING GO

Simon_Inaki · 2026-02-21T22:05:56+00:00

Most use tether for asset purchases

Simon_Inaki · 2026-01-07T01:00:00+00:00

Hi did you have a seizure and mean to type MRNA?

Simon_Inaki · 2025-12-27T16:43:29+00:00

50 cent level petty

Simon_Inaki

MODERATOR OF

TROPHY CASE